Mark W Ball1, Alan W Partin2, Jonathan I Epstein2. 1. Department of Urology, The Johns Hopkins Medical Institutions, Baltimore, MD. Electronic address: mark.ball@jhmi.edu. 2. Department of Urology, The Johns Hopkins Medical Institutions, Baltimore, MD; Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, MD; Department of Oncology, The Johns Hopkins Medical Institutions, Baltimore, MD.
Abstract
OBJECTIVE: To evaluate the impact of the extent of extraprostatic extension (EPE) on biochemical recurrence-free survival (BCRFS) after radical prostatectomy (RP). MATERIALS AND METHODS: We queried our RP database from 2004 to 2013. Extent of EPE on RP was divided into 3 groups: no EPE, focal EPE (F-EPE; a few extraprostatic cancer glands on 1-2 slides), and nonfocal EPE (NF-EPE). Multivariate Cox proportional hazard models determined the influence of EPE on BCRFS. RESULTS: A total of 10,750 men underwent RP during the study period. Of these, 7843 men (73.0%) had no EPE, 1258 (11.7%) men had F-EPE, and 1649 men had (15.3%) NF-EPE. Overall BCRFS was worse in men with NF-EPE than those with F-EPE or no EPE. In a multivariate model, F-EPE and NF-EPE were both independently associated with worse BCRFS compared with no EPE (F-EPE: hazard ratio, 2.41; 95% confidence interval, 1.84-3.10; P <.0001; NF-EPE: hazard ratio, 3.57; 95% confidence interval, 2.89-4.40; P <.0001). When stratified by Gleason score in men without seminal vesicle invasion or lymph node metastases, there was no difference in BCRFS for Gleason score <6, 3 + 4 = 7, 4 + 3 = 7, and 8 for F-EPE vs no EPE; however, patients with Gleason score of 9-10 with F-EPE had worse BCRFS. Patients with NF-EPE had significantly worse BCRFS for Gleason score <6, 7, and 8 and a trend for worse BCRFS for Gleason score 9-10 compared with no EPE. CONCLUSION: Although all men with EPE have higher BCRFS after RP, men with NF-EPE have worse BCRFS than those with F-EPE, supporting the need to substratify pT3a prostate cancer in the American Joint Committee on Cancer staging system.
OBJECTIVE: To evaluate the impact of the extent of extraprostatic extension (EPE) on biochemical recurrence-free survival (BCRFS) after radical prostatectomy (RP). MATERIALS AND METHODS: We queried our RP database from 2004 to 2013. Extent of EPE on RP was divided into 3 groups: no EPE, focal EPE (F-EPE; a few extraprostatic cancer glands on 1-2 slides), and nonfocal EPE (NF-EPE). Multivariate Cox proportional hazard models determined the influence of EPE on BCRFS. RESULTS: A total of 10,750 men underwent RP during the study period. Of these, 7843 men (73.0%) had no EPE, 1258 (11.7%) men had F-EPE, and 1649 men had (15.3%) NF-EPE. Overall BCRFS was worse in men with NF-EPE than those with F-EPE or no EPE. In a multivariate model, F-EPE and NF-EPE were both independently associated with worse BCRFS compared with no EPE (F-EPE: hazard ratio, 2.41; 95% confidence interval, 1.84-3.10; P <.0001; NF-EPE: hazard ratio, 3.57; 95% confidence interval, 2.89-4.40; P <.0001). When stratified by Gleason score in men without seminal vesicle invasion or lymph node metastases, there was no difference in BCRFS for Gleason score <6, 3 + 4 = 7, 4 + 3 = 7, and 8 for F-EPE vs no EPE; however, patients with Gleason score of 9-10 with F-EPE had worse BCRFS. Patients with NF-EPE had significantly worse BCRFS for Gleason score <6, 7, and 8 and a trend for worse BCRFS for Gleason score 9-10 compared with no EPE. CONCLUSION: Although all men with EPE have higher BCRFS after RP, men with NF-EPE have worse BCRFS than those with F-EPE, supporting the need to substratify pT3a prostate cancer in the American Joint Committee on Cancer staging system.
Authors: Alessandro Conti; Matteo Santoni; Luciano Burattini; Marina Scarpelli; Roberta Mazzucchelli; Andrea B Galosi; Liang Cheng; Antonio Lopez-Beltran; Alberto Briganti; Francesco Montorsi; Rodolfo Montironi Journal: World J Urol Date: 2015-12-22 Impact factor: 4.226
Authors: T Maubon; N Branger; C Bastide; G Lonjon; K-A Harvey-Bryan; P Validire; S Giusiano; D Rossi; X Cathelineau; F Rozet Journal: Prostate Cancer Prostatic Dis Date: 2016-07-12 Impact factor: 5.554
Authors: Mark K Buyyounouski; Peter L Choyke; Jesse K McKenney; Oliver Sartor; Howard M Sandler; Mahul B Amin; Michael W Kattan; Daniel W Lin Journal: CA Cancer J Clin Date: 2017-02-21 Impact factor: 508.702
Authors: Lars A R Reisæter; Ole J Halvorsen; Christian Beisland; Alfred Honoré; Karsten Gravdal; Are Losnegård; Jan Monssen; Lars A Akslen; Martin Biermann Journal: Radiol Imaging Cancer Date: 2020-01-17
Authors: Julien Le Nobin; Andrew B Rosenkrantz; Arnauld Villers; Clément Orczyk; Fang-Ming Deng; Jonathan Melamed; Artem Mikheev; Henry Rusinek; Samir S Taneja Journal: J Urol Date: 2015-02-21 Impact factor: 7.450
Authors: Lucas W Dean; Melissa Assel; Daniel D Sjoberg; Andrew J Vickers; Hikmat A Al-Ahmadie; Ying-Bei Chen; Anuradha Gopalan; S Joseph Sirintrapun; Satish K Tickoo; James A Eastham; Peter T Scardino; Victor E Reuter; Behfar Ehdaie; Samson W Fine Journal: J Urol Date: 2019-01 Impact factor: 7.450
Authors: Trevor A Flood; Nicola Schieda; Jordan Sim; Rodney H Breau; Chris Morash; Eric C Belanger; Susan J Robertson Journal: Virchows Arch Date: 2017-10-03 Impact factor: 4.064